Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Smoking Cessation | 54 | 2024 | 2084 | 7.190 |
Why?
|
Tobacco Use Disorder | 31 | 2024 | 708 | 6.200 |
Why?
|
Cannabis | 17 | 2024 | 446 | 4.560 |
Why?
|
Nicotinic Agonists | 19 | 2021 | 266 | 4.190 |
Why?
|
Marijuana Abuse | 12 | 2024 | 409 | 4.050 |
Why?
|
Bupropion | 20 | 2022 | 304 | 3.660 |
Why?
|
Nicotine | 18 | 2024 | 681 | 3.170 |
Why?
|
Schizophrenia | 54 | 2024 | 6987 | 3.100 |
Why?
|
Marijuana Smoking | 8 | 2019 | 261 | 3.050 |
Why?
|
Tobacco Use Cessation | 6 | 2024 | 100 | 2.560 |
Why?
|
Smoking | 39 | 2024 | 9094 | 2.410 |
Why?
|
Reward | 10 | 2024 | 985 | 1.810 |
Why?
|
Schizophrenic Psychology | 21 | 2017 | 1651 | 1.630 |
Why?
|
Quinoxalines | 6 | 2021 | 297 | 1.480 |
Why?
|
Benzazepines | 6 | 2021 | 309 | 1.480 |
Why?
|
Antipsychotic Agents | 29 | 2020 | 3081 | 1.400 |
Why?
|
Substance Withdrawal Syndrome | 6 | 2023 | 628 | 1.170 |
Why?
|
Double-Blind Method | 45 | 2024 | 12469 | 1.160 |
Why?
|
Cues | 7 | 2018 | 884 | 1.140 |
Why?
|
Dopamine Uptake Inhibitors | 5 | 2016 | 298 | 1.120 |
Why?
|
Mental Disorders | 13 | 2024 | 6879 | 1.100 |
Why?
|
Cycloserine | 6 | 2018 | 118 | 1.070 |
Why?
|
Psychotic Disorders | 16 | 2022 | 3279 | 0.970 |
Why?
|
Substance-Related Disorders | 9 | 2024 | 4429 | 0.940 |
Why?
|
Behavior, Addictive | 5 | 2024 | 433 | 0.890 |
Why?
|
Bipolar Disorder | 8 | 2019 | 5131 | 0.870 |
Why?
|
Attention | 12 | 2019 | 2425 | 0.840 |
Why?
|
Cannabidiol | 2 | 2022 | 123 | 0.810 |
Why?
|
Adult | 117 | 2024 | 223818 | 0.780 |
Why?
|
Peer Group | 3 | 2019 | 698 | 0.770 |
Why?
|
Clozapine | 14 | 2010 | 509 | 0.760 |
Why?
|
Motivation | 5 | 2024 | 2030 | 0.740 |
Why?
|
Cross-Over Studies | 10 | 2024 | 2108 | 0.670 |
Why?
|
Depressive Disorder, Major | 8 | 2023 | 4819 | 0.670 |
Why?
|
Implosive Therapy | 2 | 2018 | 127 | 0.670 |
Why?
|
Impulsive Behavior | 3 | 2024 | 349 | 0.660 |
Why?
|
Cerebral Cortex | 8 | 2024 | 5834 | 0.640 |
Why?
|
Adolescent Behavior | 3 | 2024 | 1190 | 0.640 |
Why?
|
Anxiety Disorders | 8 | 2023 | 2748 | 0.620 |
Why?
|
Young Adult | 37 | 2024 | 60110 | 0.610 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2024 | 752 | 0.600 |
Why?
|
Adolescent | 41 | 2024 | 89247 | 0.600 |
Why?
|
Behavior Therapy | 6 | 2024 | 886 | 0.600 |
Why?
|
Mood Disorders | 4 | 2022 | 1129 | 0.590 |
Why?
|
Humans | 169 | 2024 | 768887 | 0.580 |
Why?
|
Anticipation, Psychological | 1 | 2018 | 91 | 0.570 |
Why?
|
Brain | 17 | 2024 | 27476 | 0.560 |
Why?
|
Sleep Initiation and Maintenance Disorders | 3 | 2024 | 1106 | 0.540 |
Why?
|
Female | 112 | 2024 | 397464 | 0.520 |
Why?
|
Risperidone | 5 | 2010 | 383 | 0.520 |
Why?
|
Verbal Learning | 3 | 2019 | 465 | 0.510 |
Why?
|
Prefrontal Cortex | 4 | 2024 | 2257 | 0.500 |
Why?
|
Cholinesterase Inhibitors | 3 | 2008 | 241 | 0.500 |
Why?
|
Male | 103 | 2024 | 365249 | 0.500 |
Why?
|
Glycine | 3 | 2011 | 672 | 0.500 |
Why?
|
Middle Aged | 76 | 2024 | 223740 | 0.480 |
Why?
|
Cotinine | 3 | 2022 | 206 | 0.480 |
Why?
|
Antidepressive Agents, Second-Generation | 4 | 2015 | 492 | 0.470 |
Why?
|
Self Care | 1 | 2020 | 801 | 0.470 |
Why?
|
Risk-Taking | 2 | 2023 | 1025 | 0.470 |
Why?
|
Reaction Time | 8 | 2019 | 2102 | 0.460 |
Why?
|
Self Report | 5 | 2024 | 3773 | 0.460 |
Why?
|
Mecamylamine | 1 | 2013 | 27 | 0.450 |
Why?
|
Neurofeedback | 1 | 2014 | 50 | 0.440 |
Why?
|
Nicotinic Antagonists | 1 | 2013 | 94 | 0.430 |
Why?
|
Memory | 5 | 2018 | 2210 | 0.430 |
Why?
|
Brain Mapping | 5 | 2019 | 6740 | 0.430 |
Why?
|
Cognition | 8 | 2024 | 7080 | 0.430 |
Why?
|
Propranolol | 1 | 2014 | 493 | 0.420 |
Why?
|
Magnetic Resonance Imaging | 16 | 2024 | 36861 | 0.410 |
Why?
|
Corpus Striatum | 2 | 2018 | 1237 | 0.400 |
Why?
|
Maternal Behavior | 1 | 2014 | 309 | 0.400 |
Why?
|
Choice Behavior | 2 | 2015 | 848 | 0.390 |
Why?
|
Psychiatric Status Rating Scales | 17 | 2017 | 6031 | 0.380 |
Why?
|
Alcoholism | 3 | 2018 | 1981 | 0.370 |
Why?
|
Fluoxetine | 1 | 2015 | 735 | 0.370 |
Why?
|
Neuropsychological Tests | 12 | 2021 | 7148 | 0.360 |
Why?
|
Antimanic Agents | 2 | 2006 | 524 | 0.360 |
Why?
|
Mother-Child Relations | 1 | 2014 | 500 | 0.350 |
Why?
|
Narcotic Antagonists | 3 | 2014 | 591 | 0.350 |
Why?
|
Social Environment | 1 | 2015 | 1016 | 0.340 |
Why?
|
Drug Therapy, Combination | 16 | 2018 | 6320 | 0.340 |
Why?
|
Weight Gain | 4 | 2023 | 2359 | 0.340 |
Why?
|
Administration, Cutaneous | 6 | 2011 | 716 | 0.340 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2339 | 0.340 |
Why?
|
Delayed-Action Preparations | 8 | 2011 | 969 | 0.330 |
Why?
|
Alcohol Drinking | 2 | 2020 | 4045 | 0.330 |
Why?
|
Pyrrolidines | 1 | 2011 | 342 | 0.330 |
Why?
|
Analysis of Variance | 7 | 2016 | 6242 | 0.330 |
Why?
|
Treatment Outcome | 35 | 2024 | 65485 | 0.330 |
Why?
|
Combined Modality Therapy | 10 | 2018 | 8559 | 0.320 |
Why?
|
Cognition Disorders | 8 | 2009 | 3985 | 0.320 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2014 | 1243 | 0.310 |
Why?
|
Indans | 2 | 2006 | 92 | 0.310 |
Why?
|
Cholinergic Agonists | 1 | 2008 | 75 | 0.300 |
Why?
|
Galantamine | 1 | 2008 | 33 | 0.300 |
Why?
|
Cocaine-Related Disorders | 2 | 2008 | 461 | 0.300 |
Why?
|
Psychomotor Performance | 4 | 2011 | 1895 | 0.290 |
Why?
|
Mental Recall | 2 | 2016 | 1226 | 0.280 |
Why?
|
Valproic Acid | 2 | 2006 | 444 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2022 | 10397 | 0.270 |
Why?
|
Nerve Net | 2 | 2019 | 2361 | 0.260 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 905 | 0.260 |
Why?
|
Quinolines | 1 | 2011 | 772 | 0.260 |
Why?
|
Anxiety | 3 | 2024 | 4677 | 0.260 |
Why?
|
Suicide | 1 | 2017 | 1606 | 0.260 |
Why?
|
Memory, Short-Term | 3 | 2024 | 1010 | 0.260 |
Why?
|
Benzodiazepines | 8 | 2020 | 1139 | 0.250 |
Why?
|
Depression | 4 | 2024 | 8240 | 0.250 |
Why?
|
Lithium Carbonate | 1 | 2006 | 179 | 0.250 |
Why?
|
Decision Making | 2 | 2016 | 3952 | 0.250 |
Why?
|
Inositol | 1 | 2006 | 216 | 0.240 |
Why?
|
Suicidal Ideation | 2 | 2024 | 1462 | 0.240 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2016 | 9081 | 0.240 |
Why?
|
Time Factors | 11 | 2020 | 40266 | 0.230 |
Why?
|
Emotions | 3 | 2014 | 2768 | 0.220 |
Why?
|
Psychoses, Substance-Induced | 2 | 2016 | 98 | 0.220 |
Why?
|
Comorbidity | 10 | 2019 | 10591 | 0.210 |
Why?
|
Tandem Mass Spectrometry | 2 | 2019 | 1197 | 0.200 |
Why?
|
Cannabinoids | 2 | 2024 | 175 | 0.200 |
Why?
|
Massachusetts | 3 | 2021 | 8888 | 0.200 |
Why?
|
Legislation, Drug | 2 | 2022 | 216 | 0.200 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 3743 | 0.200 |
Why?
|
Hazardous Substances | 1 | 2022 | 153 | 0.190 |
Why?
|
Television | 1 | 2024 | 410 | 0.190 |
Why?
|
Excitatory Amino Acid Agonists | 2 | 1999 | 142 | 0.190 |
Why?
|
Single-Blind Method | 2 | 2022 | 1585 | 0.190 |
Why?
|
Patient Dropouts | 2 | 2017 | 411 | 0.190 |
Why?
|
Glutamic Acid | 3 | 2011 | 1193 | 0.190 |
Why?
|
Gyrus Cinguli | 3 | 2017 | 1136 | 0.180 |
Why?
|
Placebos | 7 | 2009 | 1668 | 0.180 |
Why?
|
Registries | 1 | 2017 | 8384 | 0.180 |
Why?
|
Piperidines | 2 | 2006 | 1669 | 0.170 |
Why?
|
Naltrexone | 3 | 2014 | 319 | 0.170 |
Why?
|
Hallucinogens | 1 | 2024 | 212 | 0.170 |
Why?
|
Follow-Up Studies | 11 | 2020 | 39394 | 0.170 |
Why?
|
Carbon Monoxide | 2 | 2017 | 552 | 0.160 |
Why?
|
Dopamine Agonists | 2 | 2014 | 353 | 0.160 |
Why?
|
Ownership | 1 | 2022 | 344 | 0.160 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 417 | 0.160 |
Why?
|
Limit of Detection | 1 | 2019 | 277 | 0.160 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 6 | 2008 | 1989 | 0.150 |
Why?
|
Antidepressive Agents | 2 | 2011 | 2914 | 0.150 |
Why?
|
Cardiovascular Diseases | 5 | 2020 | 15662 | 0.150 |
Why?
|
Recurrence | 5 | 2017 | 8512 | 0.150 |
Why?
|
Psychological Tests | 2 | 2018 | 642 | 0.150 |
Why?
|
Heart Rate | 3 | 2024 | 4217 | 0.150 |
Why?
|
Regression Analysis | 3 | 2022 | 6346 | 0.150 |
Why?
|
Psychotherapy, Group | 1 | 2021 | 417 | 0.140 |
Why?
|
Glycemic Index | 1 | 2020 | 400 | 0.140 |
Why?
|
Benzothiazoles | 2 | 2009 | 248 | 0.140 |
Why?
|
Piperazines | 4 | 2009 | 2553 | 0.140 |
Why?
|
Antiparkinson Agents | 1 | 1998 | 184 | 0.140 |
Why?
|
Linear Models | 3 | 2016 | 5890 | 0.140 |
Why?
|
Pyrenes | 1 | 2017 | 51 | 0.140 |
Why?
|
Receptors, Dopamine D2 | 3 | 2009 | 487 | 0.140 |
Why?
|
Cross-Sectional Studies | 15 | 2024 | 26384 | 0.140 |
Why?
|
Nitrosamines | 1 | 2017 | 86 | 0.140 |
Why?
|
Weight Loss | 2 | 2019 | 2720 | 0.140 |
Why?
|
Substance Abuse Detection | 1 | 2019 | 301 | 0.140 |
Why?
|
Aged | 16 | 2024 | 171790 | 0.130 |
Why?
|
Caudate Nucleus | 1 | 2017 | 392 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 12252 | 0.130 |
Why?
|
Brief Psychiatric Rating Scale | 2 | 2006 | 108 | 0.130 |
Why?
|
Perception | 1 | 2022 | 1209 | 0.130 |
Why?
|
Cyclobutanes | 2 | 2007 | 57 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2012 | 10778 | 0.130 |
Why?
|
Depressive Disorder | 1 | 2008 | 3726 | 0.130 |
Why?
|
Immunoassay | 1 | 2019 | 746 | 0.130 |
Why?
|
Limbic System | 1 | 1998 | 425 | 0.130 |
Why?
|
Finland | 1 | 2017 | 609 | 0.130 |
Why?
|
Chromatography, Liquid | 1 | 2019 | 997 | 0.130 |
Why?
|
Appetite Depressants | 2 | 2007 | 108 | 0.130 |
Why?
|
Pennsylvania | 1 | 2017 | 615 | 0.120 |
Why?
|
Basal Ganglia | 1 | 1998 | 555 | 0.120 |
Why?
|
Personality | 1 | 2019 | 560 | 0.120 |
Why?
|
Antimetabolites | 1 | 2015 | 129 | 0.120 |
Why?
|
Smoke | 1 | 2017 | 236 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2008 | 4862 | 0.120 |
Why?
|
United States | 11 | 2024 | 73180 | 0.120 |
Why?
|
Behavior | 2 | 2016 | 543 | 0.120 |
Why?
|
Discriminant Analysis | 1 | 2015 | 222 | 0.120 |
Why?
|
Gastrectomy | 1 | 2019 | 693 | 0.120 |
Why?
|
Rest | 1 | 2019 | 951 | 0.120 |
Why?
|
Aspartic Acid | 1 | 1997 | 577 | 0.120 |
Why?
|
Neurotransmitter Agents | 1 | 1998 | 665 | 0.110 |
Why?
|
Quinolones | 2 | 2009 | 389 | 0.110 |
Why?
|
Low Back Pain | 1 | 2022 | 990 | 0.110 |
Why?
|
Longitudinal Studies | 5 | 2023 | 14795 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1119 | 0.110 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2011 | 3782 | 0.110 |
Why?
|
Internationality | 1 | 2019 | 1008 | 0.110 |
Why?
|
Tobacco Smoke Pollution | 1 | 2019 | 828 | 0.110 |
Why?
|
Probability | 2 | 2016 | 2483 | 0.110 |
Why?
|
Friends | 1 | 2014 | 148 | 0.110 |
Why?
|
Hyperprolactinemia | 1 | 2014 | 124 | 0.110 |
Why?
|
Social Facilitation | 1 | 2012 | 31 | 0.110 |
Why?
|
Risk | 2 | 2017 | 9621 | 0.100 |
Why?
|
Ambulatory Care | 6 | 2008 | 2783 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2003 | 1924 | 0.100 |
Why?
|
Galvanic Skin Response | 1 | 2014 | 359 | 0.100 |
Why?
|
Taurine | 1 | 2012 | 92 | 0.100 |
Why?
|
Telecommunications | 1 | 2012 | 79 | 0.100 |
Why?
|
Creatine | 3 | 2011 | 427 | 0.100 |
Why?
|
Extinction, Psychological | 1 | 2015 | 371 | 0.100 |
Why?
|
Dysthymic Disorder | 1 | 2011 | 73 | 0.090 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12093 | 0.090 |
Why?
|
Bariatric Surgery | 2 | 2019 | 1001 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2017 | 1445 | 0.090 |
Why?
|
Receptors, Dopamine D3 | 2 | 2009 | 109 | 0.090 |
Why?
|
Pain | 2 | 2024 | 5100 | 0.090 |
Why?
|
Neural Pathways | 2 | 2019 | 3120 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2023 | 5323 | 0.090 |
Why?
|
Cohort Studies | 4 | 2024 | 41800 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2411 | 0.090 |
Why?
|
Citalopram | 1 | 2012 | 401 | 0.080 |
Why?
|
Social Behavior | 1 | 2016 | 1146 | 0.080 |
Why?
|
Self-Help Groups | 1 | 2011 | 194 | 0.080 |
Why?
|
Dogs | 1 | 2014 | 3845 | 0.080 |
Why?
|
Task Performance and Analysis | 1 | 2013 | 771 | 0.080 |
Why?
|
Inpatients | 1 | 2021 | 2570 | 0.080 |
Why?
|
Diffusion Tensor Imaging | 1 | 2019 | 2426 | 0.080 |
Why?
|
Boston | 2 | 2024 | 9375 | 0.080 |
Why?
|
Polymethacrylic Acids | 1 | 2008 | 32 | 0.080 |
Why?
|
Chewing Gum | 1 | 2008 | 40 | 0.080 |
Why?
|
Outpatients | 1 | 2017 | 1604 | 0.080 |
Why?
|
Feeding Behavior | 2 | 2019 | 3206 | 0.080 |
Why?
|
Medicaid | 1 | 2022 | 2843 | 0.080 |
Why?
|
Memory Disorders | 1 | 2016 | 1203 | 0.080 |
Why?
|
Naloxone | 2 | 2013 | 372 | 0.080 |
Why?
|
Obesity, Morbid | 1 | 2019 | 1300 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2017 | 1672 | 0.080 |
Why?
|
Receptors, Nicotinic | 1 | 2011 | 494 | 0.070 |
Why?
|
Obesity | 7 | 2020 | 13087 | 0.070 |
Why?
|
Polyvinyls | 1 | 2008 | 156 | 0.070 |
Why?
|
Pilot Projects | 6 | 2017 | 8742 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15955 | 0.070 |
Why?
|
Blood Glucose | 6 | 2010 | 6434 | 0.070 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2008 | 213 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2649 | 0.070 |
Why?
|
Anthropometry | 2 | 2009 | 1343 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2022 | 2189 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7460 | 0.070 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 5892 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2019 | 4642 | 0.070 |
Why?
|
Oxygen | 2 | 2016 | 4273 | 0.070 |
Why?
|
Injections, Intramuscular | 1 | 2008 | 556 | 0.070 |
Why?
|
Causality | 1 | 2012 | 1255 | 0.070 |
Why?
|
Psychometrics | 3 | 2023 | 3066 | 0.060 |
Why?
|
Dibenzothiazepines | 1 | 2006 | 102 | 0.060 |
Why?
|
Association Learning | 1 | 2007 | 223 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14751 | 0.060 |
Why?
|
Sulfones | 1 | 2008 | 448 | 0.060 |
Why?
|
Oxidative Stress | 1 | 2017 | 3138 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2013 | 18065 | 0.060 |
Why?
|
Waist Circumference | 1 | 2009 | 935 | 0.060 |
Why?
|
Age of Onset | 1 | 2012 | 3346 | 0.060 |
Why?
|
Glucose | 4 | 2010 | 4352 | 0.060 |
Why?
|
Child | 4 | 2024 | 80969 | 0.060 |
Why?
|
Prospective Studies | 2 | 2020 | 54950 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2011 | 1476 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20244 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2015 | 2714 | 0.060 |
Why?
|
Pyridines | 1 | 2017 | 2896 | 0.060 |
Why?
|
Risk Factors | 7 | 2020 | 74971 | 0.060 |
Why?
|
Glucose Tolerance Test | 4 | 2010 | 1183 | 0.060 |
Why?
|
Insulin Resistance | 5 | 2010 | 3982 | 0.060 |
Why?
|
Gross Domestic Product | 1 | 2024 | 77 | 0.060 |
Why?
|
Lithium Compounds | 1 | 2006 | 226 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2017 | 22294 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15471 | 0.060 |
Why?
|
Sample Size | 1 | 2007 | 848 | 0.060 |
Why?
|
Models, Biological | 2 | 2019 | 9499 | 0.050 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2007 | 365 | 0.050 |
Why?
|
Morbidity | 2 | 2009 | 1757 | 0.050 |
Why?
|
Hyperlipidemias | 2 | 2005 | 773 | 0.050 |
Why?
|
Quality of Life | 4 | 2022 | 13510 | 0.050 |
Why?
|
Incidence | 2 | 2017 | 21545 | 0.050 |
Why?
|
Buprenorphine | 2 | 2013 | 667 | 0.050 |
Why?
|
Long QT Syndrome | 1 | 2008 | 472 | 0.050 |
Why?
|
Tobacco Industry | 1 | 2024 | 138 | 0.050 |
Why?
|
Counseling | 2 | 2022 | 1554 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4593 | 0.050 |
Why?
|
Benzhydryl Compounds | 1 | 2009 | 943 | 0.050 |
Why?
|
Arousal | 1 | 2008 | 1183 | 0.050 |
Why?
|
Marketing | 1 | 2024 | 224 | 0.050 |
Why?
|
Dietary Fats | 1 | 2010 | 2003 | 0.050 |
Why?
|
Pirenzepine | 1 | 2002 | 116 | 0.050 |
Why?
|
Thiazoles | 1 | 2009 | 1542 | 0.050 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2012 | 300 | 0.050 |
Why?
|
Computer Simulation | 1 | 2015 | 6289 | 0.050 |
Why?
|
Homocysteine | 1 | 2004 | 637 | 0.050 |
Why?
|
Hypertension | 3 | 2020 | 8615 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10845 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5956 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 330 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 2009 | 1182 | 0.040 |
Why?
|
Child, Preschool | 2 | 2014 | 42684 | 0.040 |
Why?
|
Social Control, Formal | 1 | 2001 | 107 | 0.040 |
Why?
|
Receptors, GABA | 1 | 2022 | 313 | 0.040 |
Why?
|
Research Design | 2 | 2015 | 6213 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.040 |
Why?
|
Drug Resistance | 1 | 2006 | 1600 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 640 | 0.040 |
Why?
|
New York | 1 | 2022 | 884 | 0.040 |
Why?
|
Learning | 1 | 2009 | 1761 | 0.040 |
Why?
|
Prescriptions | 1 | 2022 | 388 | 0.040 |
Why?
|
Body Weight | 5 | 2009 | 4628 | 0.040 |
Why?
|
Placebo Effect | 1 | 2003 | 518 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3709 | 0.040 |
Why?
|
Mental Health | 2 | 2024 | 3275 | 0.040 |
Why?
|
Haloperidol | 1 | 2020 | 394 | 0.040 |
Why?
|
Reinforcement Schedule | 2 | 2009 | 123 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4415 | 0.040 |
Why?
|
Bronchiolitis | 1 | 2004 | 492 | 0.040 |
Why?
|
Child Behavior | 1 | 2024 | 865 | 0.040 |
Why?
|
Body Mass Index | 7 | 2009 | 13054 | 0.040 |
Why?
|
Folic Acid | 1 | 2004 | 1336 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4251 | 0.040 |
Why?
|
Gene Expression | 1 | 2010 | 7602 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2003 | 8055 | 0.030 |
Why?
|
Anisotropy | 1 | 2019 | 1295 | 0.030 |
Why?
|
Lung Diseases, Interstitial | 1 | 2004 | 944 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2024 | 1423 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2025 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1409 | 0.030 |
Why?
|
Cytokines | 1 | 2010 | 7453 | 0.030 |
Why?
|
Random Allocation | 1 | 2019 | 2396 | 0.030 |
Why?
|
Ergolines | 1 | 2014 | 57 | 0.030 |
Why?
|
Basal Ganglia Diseases | 2 | 2004 | 145 | 0.030 |
Why?
|
Cholesterol | 3 | 2009 | 2913 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2193 | 0.030 |
Why?
|
Students | 1 | 2024 | 1744 | 0.030 |
Why?
|
Logistic Models | 1 | 2008 | 13317 | 0.030 |
Why?
|
Age Factors | 3 | 2018 | 18454 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2019 | 1428 | 0.030 |
Why?
|
Pneumonia | 1 | 2004 | 2163 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2357 | 0.030 |
Why?
|
Animals | 2 | 2015 | 169408 | 0.030 |
Why?
|
Psychiatry | 1 | 2005 | 1716 | 0.030 |
Why?
|
Psychotropic Drugs | 1 | 2018 | 883 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2012 | 26394 | 0.020 |
Why?
|
International Cooperation | 1 | 2018 | 1436 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2021 | 2660 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 30175 | 0.020 |
Why?
|
Stroop Test | 1 | 2010 | 72 | 0.020 |
Why?
|
Infant | 1 | 2012 | 36541 | 0.020 |
Why?
|
Administration, Oral | 2 | 2009 | 4042 | 0.020 |
Why?
|
Triglycerides | 2 | 2009 | 2464 | 0.020 |
Why?
|
Blood Pressure | 2 | 2020 | 8541 | 0.020 |
Why?
|
Feedback, Psychological | 1 | 2009 | 97 | 0.020 |
Why?
|
Lipids | 1 | 2020 | 3345 | 0.020 |
Why?
|
Internal-External Control | 1 | 2010 | 350 | 0.020 |
Why?
|
Life Style | 1 | 2020 | 3931 | 0.020 |
Why?
|
Alleles | 2 | 2011 | 6901 | 0.020 |
Why?
|
Diet Records | 1 | 2010 | 426 | 0.020 |
Why?
|
Prognosis | 2 | 2019 | 30044 | 0.020 |
Why?
|
Primary Health Care | 1 | 2024 | 4748 | 0.020 |
Why?
|
Sleep | 1 | 2023 | 4820 | 0.020 |
Why?
|
Motor Activity | 1 | 2017 | 2722 | 0.020 |
Why?
|
Connective Tissue | 1 | 1990 | 425 | 0.020 |
Why?
|
Occipital Lobe | 1 | 2009 | 376 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2010 | 948 | 0.020 |
Why?
|
Hippocampus | 1 | 2019 | 3786 | 0.020 |
Why?
|
Food Preferences | 1 | 2010 | 398 | 0.020 |
Why?
|
Lung | 1 | 2004 | 10097 | 0.020 |
Why?
|
Sialorrhea | 1 | 2005 | 25 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3837 | 0.020 |
Why?
|
Discrimination Learning | 1 | 2007 | 278 | 0.020 |
Why?
|
Community Mental Health Centers | 1 | 2006 | 93 | 0.020 |
Why?
|
Pneumothorax | 1 | 1989 | 393 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7860 | 0.020 |
Why?
|
Health Status | 2 | 2009 | 4095 | 0.020 |
Why?
|
Capsules | 1 | 2005 | 193 | 0.020 |
Why?
|
Dyskinesias | 1 | 2005 | 79 | 0.020 |
Why?
|
Purines | 1 | 2008 | 615 | 0.020 |
Why?
|
Mass Screening | 1 | 2021 | 5455 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5520 | 0.010 |
Why?
|
Nausea | 1 | 2007 | 682 | 0.010 |
Why?
|
Dizziness | 1 | 2007 | 269 | 0.010 |
Why?
|
Cause of Death | 2 | 2005 | 3721 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2862 | 0.010 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2004 | 90 | 0.010 |
Why?
|
Protons | 1 | 2009 | 1113 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15875 | 0.010 |
Why?
|
Bronchoscopy | 1 | 1989 | 914 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5953 | 0.010 |
Why?
|
Evoked Potentials | 1 | 2009 | 1058 | 0.010 |
Why?
|
Eating | 1 | 2010 | 1542 | 0.010 |
Why?
|
Prostheses and Implants | 1 | 1990 | 1279 | 0.010 |
Why?
|
Life Change Events | 1 | 2008 | 962 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 1989 | 1321 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2006 | 740 | 0.010 |
Why?
|
Stereotyping | 1 | 2004 | 241 | 0.010 |
Why?
|
Wakefulness | 1 | 2009 | 1284 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12798 | 0.010 |
Why?
|
Fatigue | 1 | 2009 | 1557 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2007 | 2931 | 0.010 |
Why?
|
Cardiomegaly | 1 | 2004 | 591 | 0.010 |
Why?
|
Psychotherapy | 1 | 2011 | 1654 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2007 | 81892 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 2004 | 528 | 0.010 |
Why?
|
Criminal Psychology | 1 | 2001 | 15 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 1990 | 1703 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2010 | 1904 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 3438 | 0.010 |
Why?
|
Orthopedics | 1 | 1990 | 906 | 0.010 |
Why?
|
Chronic Disease | 2 | 2009 | 9384 | 0.010 |
Why?
|
Hemoglobins | 1 | 2007 | 1531 | 0.010 |
Why?
|
Cough | 1 | 2004 | 598 | 0.010 |
Why?
|
Fasting | 1 | 2007 | 1610 | 0.010 |
Why?
|
Hyperglycemia | 1 | 2009 | 1389 | 0.010 |
Why?
|
Awareness | 1 | 2004 | 653 | 0.010 |
Why?
|
Poisson Distribution | 1 | 2001 | 508 | 0.010 |
Why?
|
Crime | 1 | 2001 | 206 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2010 | 5505 | 0.010 |
Why?
|
Employment | 1 | 2004 | 1114 | 0.010 |
Why?
|
Overweight | 1 | 2009 | 2445 | 0.010 |
Why?
|
Primary Prevention | 1 | 2005 | 1187 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2009 | 3858 | 0.010 |
Why?
|
Behavioral Symptoms | 1 | 1999 | 188 | 0.010 |
Why?
|
Dyspnea | 1 | 2004 | 1352 | 0.010 |
Why?
|
Communicable Diseases | 1 | 2005 | 873 | 0.010 |
Why?
|
Odds Ratio | 1 | 2007 | 9682 | 0.010 |
Why?
|
Health Promotion | 1 | 2007 | 2210 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 59738 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4941 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2001 | 941 | 0.010 |
Why?
|
Drug Interactions | 1 | 1999 | 1421 | 0.010 |
Why?
|
Patient Compliance | 1 | 2004 | 2701 | 0.010 |
Why?
|
Radiography | 1 | 2004 | 6991 | 0.010 |
Why?
|
Sex Factors | 1 | 2007 | 10641 | 0.010 |
Why?
|
Electroencephalography | 1 | 2009 | 6318 | 0.010 |
Why?
|
Biopsy | 1 | 2004 | 6805 | 0.010 |
Why?
|
Survival Analysis | 1 | 2005 | 10115 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 16051 | 0.010 |
Why?
|
Insulin | 1 | 2006 | 6610 | 0.010 |
Why?
|
Coronary Disease | 1 | 2005 | 5919 | 0.010 |
Why?
|
Connective Tissue Cells | 1 | 1990 | 50 | 0.010 |
Why?
|
Chromium Alloys | 1 | 1990 | 71 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 3253 | 0.010 |
Why?
|
Alloys | 1 | 1990 | 111 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2004 | 13020 | 0.010 |
Why?
|
Titanium | 1 | 1990 | 495 | 0.000 |
Why?
|
Algorithms | 1 | 2007 | 14199 | 0.000 |
Why?
|
Diet | 1 | 2004 | 8090 | 0.000 |
Why?
|
Costs and Cost Analysis | 1 | 1989 | 1669 | 0.000 |
Why?
|
Collagen | 1 | 1990 | 2646 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1990 | 19023 | 0.000 |
Why?
|